Can stem cell mist heal lungs damaged by cancer immunotherapy?
NCT ID NCT07599111
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether inhaling tiny particles from stem cells (exosomes) can help heal lung inflammation caused by immunotherapy drugs. The study involves 40 adults with cancer who have persistent lung problems despite standard steroid treatment. Participants will inhale either the exosome mist or a placebo twice daily for a week, and researchers will track lung healing and safety for 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nebulized human umbilical cord mesenchymal stem cell-derived exosomes
What this could lead to
If it works, this could offer a new way to treat lung inflammation caused by immunotherapy, potentially reducing the need for steroids.
What could go wrong
This is a very early, small study (40 people) focused on safety. The treatment is experimental, and it may not improve lung lesions or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXOSOMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••